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Abstract 
 
Depression is a major health problem worldwide. Most prescribed antidepressants, 
the selective serotonin reuptake inhibitors (SSRI) show limited efficacy and delayed 
onset of action, partly due to the activation of somatodendritic 5-HT1A-autoreceptors 
by the excess extracellular serotonin (5-HT) produced by SSRI in the raphe nuclei. 
Likewise, 5-HT1A receptor (5-HT1AR) gene polymorphisms leading to high 5-HT1A-
autoreceptor expression increase depression susceptibility and decrease treatment 
response. Here we report on a new treatment strategy based on the administration of 
small interfering RNA (siRNA) to acutely suppress 5-HT1A-autoreceptor-mediated 
negative feedback mechanisms. We developed a conjugated siRNA (C-1A-siRNA) 
by covalently binding siRNA targeting 5-HT1A receptor mRNA with the SSRI sertraline 
in order to concentrate it in serotonin axons, rich in serotonin transporter (SERT) 
sites. The intracerebroventricular (i.c.v.) infusion of C-1A-siRNA to mice resulted in its 
selective accumulation in serotonin neurons. This evoked marked antidepressant-like 
effects in the forced swim and tail suspension tests but did not affect anxiety-like 
behaviors in the elevated plus-maze. In parallel, C-1A-siRNA administration markedly 
decreased 5-HT1A-autoreceptor expression and suppressed 8-OH-DPAT-induced 
hypothermia (a presynaptic 5-HT1AR effect in mice) without affecting postsynaptic 5-
HT1AR expression in hippocampus and prefrontal cortex. Moreover, i.c.v. C-1A-
siRNA infusion augmented the increase in extracellular serotonin evoked by 
fluoxetine in prefrontal cortex to the level seen in 5-HT1AR knockout mice. 
Interestingly, intranasal C-1A-siRNA administration produced the same effects, thus 
opening the way to the therapeutic use of C-1A-siRNA. Hence, C-1A-siRNA 
represents a new approach to treat mood disorders, as monotherapy or in 
combination with SSRI. 
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Introduction  
Major depression is a severe and heterogeneous psychiatric disease with high, 
increasing prevalence and socio-economic impact.1-3 The serotonergic system is 
implicated in the etiology and treatment of mood disorders.2 Most prescribed 
antidepressants, the selective serotonin (5-HT)  reuptake inhibitors (SSRI) and the 
dual 5-HT and norepinephrine reuptake inhibitors block physiological reuptake 
mechanisms in serotonergic axons and thereby increase extracellular 5-HT 
concentration to activate postsynaptic 5-HT receptors (5-HT1AR)  required for clinical 
effects. However, this process is severely compromised by the simultaneous 
activation of somatodendritic 5-HT1A-autoreceptors in the midbrain raphe nuclei. 5-
HT1A-autoreceptor activation reduces serotonergic activity and forebrain 5-HT 
release, an effect contrary to that required for therapeutic response.4-6  
Hence, the limited clinical efficacy of 5-HT-enhancing drugs and their delayed 
action are partly due to this negative feedback mechanism. Upon chronic treatment, 
5-HT1A-autoreceptors desensitize, leading to the recovery of serotonergic activity and 
5-HT release.5,6 Individuals with elevated density or activity of 5-HT1A-autoreceptors 
are more susceptible to mood disorders and respond poorly to antidepressants.7-9  
5-HT1AR antagonists might thus be useful to improve antidepressant therapy 
by preventing the 5-HT1A-autoreceptor-mediated negative feedback. However, the 
activation of postsynaptic 5-HT1AR is a necessary step for antidepressant effects10 
which limits the usefulness of this strategy. Thus, unlike the non-selective 5-HT1AR/ß-
adrenoceptor antagonist pindolol11,12 (with a preferential action at 5-HT1A-
autoreceptors),13,14 the selective 5-HT1AR antagonist DU-125530 does not enhance 
clinical fluoxetine effects (Scorza et al., in preparation).  
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Here we report on a new antidepressant strategy, based on the use of small 
interfering RNA (siRNA) targeted to serotonin neurons, to selectively reduce the 
expression and function of presynaptic (but not postsynaptic) 5-HT1AR. We have 
developed a conjugated 5-HT1AR siRNA (C-1A-siRNA) directed to serotonin neurons, 
by covalently binding 5-HT1AR siRNA molecules to the SSRI sertraline. Our working 
hypotheses were: a) the presence of sertraline would allow the selective 
accumulation of C-1A-siRNA in serotonin neurons, and b) the selective 5-HT1A-
autoreceptor silencing would have antidepressant effects due to the increased 
signaling and preservation of postsynaptic 5-HT1AR activity.  
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Material and Methods  
 
Animals  
Male C57BL/6J mice (Charles River) and male homozygous 5-HT1AR knockout (1A-
KO) mice on the same background15 were used. 10-15-week old mice were housed 
under controlled conditions (22±1ºC; 12h light/dark cycle) with food and water 
available ad libitum. Animal procedures were conducted in accordance with standard 
ethical guidelines (European Union regulations L35/118/12/1986) and approved by 
the local ethical committee.  
 
siRNAs  
Four unmodified siRNAs (nt: 633-651, 852-870, 1889-1907 and 2167-2185, 
GenBank accession #NM_008308) targeting the 5-HT1AR (1A-siRNA1 to 1A-siRNA4) 
were chosen for in vivo studies and administered as a mixture, containing an equal 
amount of each siRNA duplex. In addition, an unrelated siRNA duplex with no 
homology to mouse genome was used as negative control (nonsense siRNA – ns-
siRNA). All siRNAs, consisted of two complementary 21-nucleotide RNA strand with 
3´dTdT overhangs and were prepared according to the manufacturer’s protocol 
(Ambion, Inc.). Conjugated siRNA against 5-HT1AR (C-1A-siRNA) and conjugated 
nonsense siRNA (C-ns-siRNA) were synthesized by nLife Therapeutics, S.L. as 
described (International patent application PCT/EP2011/056270). Each specific 
siRNA sequence against 5-HT1AR (1A-siRNA1 to 1A-siRNA4) and ns-siRNA was 
designed to carry a substitution in each 5’-end strand (Figure 1a). Conjugated single 
strand oligonucleotides were purified by reverse-phase high performance liquid 
chromatography (HPLC). Fractions containing full-length oligonucleotides were 
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pooled, desalted, lyophilized and characterized by MALDI-TOF. Complementary 
strands were annealed in an isotonic RNA annealing buffer (100mM potassium 
acetate, 30mM HEPES-KOH pH=7.4, 2mM magnesium acetate), pre-incubated by 
1min at 90ºC, centrifuged for 15s and incubated 1h at 37ºC. Annealed products were 
HPLC-purified and siRNA-containing fractions were lyophilized. Purity was >92%. 
Similarly to unmodified siRNAs, conjugated siRNAs were used in vivo as a mixture 
consisting of an equal amount of each C-1A-siRNA. 
For experiments involving localization of C-1A-siRNA after 
intracerebroventricular (i.c.v.) infusion, each C-1A-siRNA molecule was additionally 
bound to biotin in the antisense strand. This was performed by a biotinylation 
reaction of the conjugate’s OH-free end in its terminal C18 spacer.   
We used a second strategy to generate a construct with a stronger stability 
against ribonucleases by the standard phosporamidite chemistry16,17 as described 
(International patent application PCT/EP2011/056270). A sertraline-conjugated ns-
oligonucleotide (single strand 18-mer oligonucleotide nonsense sequence, with 2’-O-
methyl ribonucleotides at positions 1 to 3 and 16 to 18, and a DNA gap of 12 
nucleobases) was synthesized with a Cy3 label at 3’ attached by a phosphodiester 
linkage. This was coupled to sertraline to examine the penetration into serotonin 
neurons after i.c.v. infusion. 
A siRNA targeting β-galactosidase (β-Gal-128) bearing a motif eliciting 
interferon production was also used.18 Stock solutions of all siRNAs were prepared 
by re-suspension of the lyophilized product in RNAse-free water and stored at -20ºC  
until use.  siRNA sequences are shown in Supplementary Table S1.  
 
Treatments 
pe
er
-0
06
65
44
4,
 v
er
sio
n 
1 
- 2
 F
eb
 2
01
2
  
   
8 
 
Intracerebral siRNA infusion. Mice were anesthetized (pentobarbital, 40mgkg-1, i.p.) 
and silica capillary microcannulae (110µm-OD, 40µm-ID; Polymicro Technologies) 
were stereotaxically implanted into dorsal raphe nucleus (DR; coordinates in mm: 
anteroposterior-AP, -4.5; mediolateral-ML, -1.0; dorsoventral-DV, -4.4; with a lateral 
angle of 20º) or in dorsal third ventricle (D3V; AP, -2.0; ML, 0; DV, -2.1).19 Some 
animals were also implanted with a microdialysis probe in medial prefrontal cortex 
(mPFC) (see below). siRNA microinfusion was performed with a perfusion pump at 
0.5µlmin-1 20–24h after surgery in awake mice. siRNAs targeting 5-HT1AR, β-
galactosidase or nonsense were prepared in artificial cerebrospinal fluid (aCSF: 
125mM NaCl, 2.5mM KCl, 1.26mM CaCl2 and 1.18mM MgCl2 with 5% glucose) and 
infused at doses of 10 or 30µg of siRNA per mouse. Intra-DR siRNA infusion was 
repeated 24h later (1-µl aliquots; two administrations in total), while i.c.v. infusion was 
performed only once into the D3V (2.5-ul aliquots). Controls and 1A-KO mice 
received aCSF.  
Intranasal siRNA administration. Pentobarbital-anesthetized mice were positioned 
lying on their backs. Phosphate buffered saline (PBS) or conjugated siRNAs (C-ns-
siRNA and C-1A-siRNA prepared in PBS) were slowly dropped alternatively into 
each nostril with a micropipette tip in 5-µl aliquots. Total administered doses were 30 
or 100µg of conjugated siRNAs.  
 
RNA isolation and quantitative RT-PCR analysis  
24-48h after the last administration of vehicle or siRNA, mice were killed and brains 
were removed. Midbrain sections containing the raphe nuclei (1-mm thick) were 
dissected out using a Mouse Brain Matrix (Ted Pella, Inc.), quickly frozen on dry ice 
and stored at -80ºC. Total RNA was isolated with Trizol solution (Invitrogen). cDNA 
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synthesis was performed using Retro-tools two steep kits (Biotools BandM labs SA). 
Quantitative RT-PCR (7900HT Fast Real-Time PCR System, Applied Biosystems) 
was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) in 
20µl of reaction mix. Cycle threshold (Ct) values were calculated using AbiPrism SDS 
2.1 software (Applied Biosystems). Data were normalized to the amount of 
CyclophilinA cDNA. Results were expressed as the unitary ratio versus vehicle 
controls. Primers sequences are given in Supplementary Table S1.  
 
Tissue preparation for in situ hybridization and receptor autoradiography 
Mice were killed by pentobarbital overdose and the brains rapidly removed, frozen on 
dry ice and stored at -20°C. Tissue sections, 14-μm thick, were cut using a 
microtome-cryostat (HM500 OM, Microm), thaw-mounted onto APTS (3-
aminopropyltriethoxysilane, Sigma-Aldrich) coated slides and kept at –20°C until use.  
 
In situ hybridization   
For 5-HT1AR mRNA, three oligonucleotides were used simultaneously, 
complementary to bases: 1-48, 763-810 and 1219-1266 (GenBank accession 
#NM_012585). These probes were synthesized with a 380 Applied Biosystem DNA 
synthesizer. Labeling of the probes and in situ hybridization procedures were carried 
out as described previously.20-22 Hybridized sections were exposed to Biomax MR 
film (Kodak) for 2-3 weeks with intensifying screens. 
  
Receptor autoradiography  
The autoradiographic binding assays for 5-HT1A and 5-HT1B receptors and serotonin 
transporter (SERT)20,23,24 were performed using the following radioligands: a) [3H]-8-
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OH-DPAT (233Cimmol-1), b) [125I]-cyanopindolol (2200Cimmol-1) and c) [3H]-
citalopram (70Cimmol-1), respectively (Amersham-GE Healthcare and Perkin-Elmer). 
8-OH-DPAT, isoproterenol, pargyline and 5-HT were from Sigma-Aldrich and 
fluoxetine was from Tocris. Experimental conditions are summarized in 
Supplementary Table S2. Tissues were exposed to Biomax MR film (Kodak) 
together with 3H-Microscales standards (Amersham-GE Healthcare). All experimental 
and control brains within a group were processed in duplicate and exposed to films 
as a batch.    
Films were analysed by microdensitometry using a computer assisted image 
analyser (AIS, Imaging Research Inc.). 5-HT1AR mRNA and 5-HT1B binding sites in 
selected brain regions were measured in the respective autoradiograms to obtain 
relative optical densities (ROD). For 5-HT1AR and SERT binding, the system was 
calibrated with 3H-Microscales standards to obtain fmol·mg-1 protein equivalents from 
ROD data. AIS system was also used to acquire pseudocolor images. Black and 
white photographs were taken from autoradiograms using a Wild 420 macroscope 
(Leica) equipped with a Nikon DXM1200 F digital camera and ACT-1 Nikon software. 
Images were processed with Photoshop (Adobe Systems, Mountain View) by using 
identical values for contrast and brightness. 
 
Immunohistochemistry  
Animals were killed by a pentobarbital overdose and perfused with 4% 
paraformaldehyde in sodium-phosphate buffer (pH=7.4). Brains were dissected, post-
fixed 24h at 4°C in the same solution, and then placed in 30% sucrose in PBS for 3 
days at 4°C. After cryopreservation, brains were embedded with gelatin, frozen and 
sectioned in a cryostat (30um coronal). Free floating sections were washed and 
pe
er
-0
06
65
44
4,
 v
er
sio
n 
1 
- 2
 F
eb
 2
01
2
  
   
11 
 
permeabilized with PBS-Triton 0.3%, blocked with BlockAid (Invitrogen) plus 0.3% 
Triton for 2h at 23°C and then incubated with NeutrAvidin (Invitrogen) 0.0125mgml-1 
in blocking solution (1h, 23°C). Sections were than washed and incubated overnight 
(4°C) with biotinylated rabbit anti-donkey antibody (Abcam) diluted 1:200, washed 
and incubated (2h, 23°C) with Cy3 conjugated donkey anti-rabbit antibody 
(Rockland) diluted 1:200 in blocking solution. This was followed by additional 
blocking with 10% donkey serum (Sigma-Aldrich) in PBS-Triton 0.3%, 1h, 23°C and 
overnight incubation with anti-tryptophanhydroxylase antibody (1:100; Chemicon-
Millipore) diluted in 3% of donkey serum in PBS-Triton 0.3%. Excess of primary 
antibody was washed and sections were incubated 2h, 23°C with AlexaFluor 647 
conjugated donkey anti-sheep antibody (Invitrogen) diluted 1:200 and YOYO-1 
(Invitrogen) diluted 1:5000 in 3% of donkey serum in PBS-Triton 0.3%. Finally, 
sections were mounted with Mowiol (Calbiochem). Samples were analyzed using a 
Leica spectral confocal microscope; data were sequentially collected from each 
channel, merged by Leica Confocal Software and 3D projections (maximal, average 
and transparent) were made from z-series. Pictures were generated using Photoshop 
(Adobe Systems, Mountain View). 
 
Intracerebral microdialysis  
Extracellular 5-HT concentration was measured by in vivo microdialysis as previously 
described.20 Briefly, one concentric dialysis probe (Cuprophan; 1mm-long) was 
implanted in mPFC (AP, 2.2; ML, -0.2; DV, -3.4)19 of pentobarbital-anaesthetized 
mice. Experiments were performed 48-72h after surgery. To assess 8-OH-DPAT 
effects on extracellular 5-HT, 1µM citalopram (SSRI; Lundbeck A/S) was added to 
aCSF.25 The aCSF was pumped at 2.0µlmin-1 (WPI model sp220i) and 30-min 
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samples were collected. 5-HT concentrations were analyzed by HPLC-amperometric 
detection (Hewlett-Packard 1049; +0.6V) with detection limits of 1.5 fmolsample-1. 
Baseline 5-HT levels were calculated as the average of the four pre-drug samples. 
Correct probe placement was verified using cresyl-violet staining. 
 
Behavioral and physiological assessments  
Mice were tested at 24-72h after treatments. Elevated plus-maze (EPM) and tail 
suspension tests (TST) were always conducted in this order, with one day between 
tests. All tests were performed between 10:00 AM-3:00 PM. On test days, animals 
were transported to the dimly illuminated behavioral laboratory and were left 
undisturbed for at least 1h before testing. 
8-OH-DPAT-induced hypothermia. Body temperature was measured intrarectally 
using a lubricated probe inserted ~2cm and a digital thermometer (AZ9882, Panlab). 
Mice were singly housed in clean cages for 20min before measurements and then 
two baseline temperature measurements were taken. Ten minutes later, animals 
received 8-OH-DPAT 1mgkg-1 i.p. and body temperature was recorded every 15min 
for a total of 120min. Data are presented as a change from the final baseline 
measurement.  
Elevated plus-maze. The elevated plus-maze was performed using a cross maze 
with 16x5cm arms illuminated from the top (100lux). Mice were placed in the central 
area, facing one of the open arms and the time and number of entries into open and 
closed arms in 5min were recorded (video camera system, Smart, Panlab). Results 
were expressed as the percentage of time and number of entries into the open arms. 
Tail suspension test. Mice were suspended 30cm above the bench by adhesive tape 
placed approximately 1cm from the tip of the tail. Mice were monitored and recorded 
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using a video camera system (Smart, Panlab) and the time spent immobile was 
recorded for 6min.  
Forced swim test (FST). Mice were individually placed into a clear cylinder (15cm 
diameter, 30cm height) containing 20cm of water maintained at 24-25ºC, essentially 
as described by Porsolt et al.26 In this test, immobility of the mouse was scored in 2-
mim bins for a total of 6min using a video camera system (Smart, Panlab).  
 
Statistical analysis 
 Data are expressed as means ± s.e.m. Data were analyzed with Student’s t-test, 
one- or two-way ANOVA, as appropriate, followed by post-hoc test (Newman-Keuls). 
The level of significance was set at P < 0.05 (two-tailed) 
Results   
 
Selective silencing of 5-HT1A-autoreceptor expression 
The potential of siRNA-based gene silencing in vivo has been limited by the lack of 
safe delivery to specific target cells.27 Previously,28 we established that local infusion 
of four siRNA sequences directed towards 5-HT1AR (1A-siRNA) into the mice DR 
reduced 5-HT1A-autoreceptor expression and function without affecting postsynaptic 
5-HT1AR, evoking a robust and rapid antidepressant-like effect. We therefore used 
the same 1A-siRNA sequences to construct C-1A-siRNA. Sense and antisense 
strands were chemically conjugated in each 5’-end strand whereas the sense strand 
was covalently bound to the SSRI-sertraline (Figure 1a). This modification was 
intended to direct C-1A-siRNA molecules to 5-HT axons, extremely rich in axonal 
varicosities (>106/mm3)29, expressing SERT, for which sertraline shows very high 
affinity (Ki=0.29nM, http://kidb.case.edu/pdsp.php).   
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 Forty eight h after stereotaxic infusion in the D3V (30µg/mouse, as in receptor 
expression and functional experiments; see below), the C-1A-siRNA construct was 
detected in midbrain serotonergic neuropil, rich in dendrites and initial axonal 
segments (Figure 1b, Supplementary Figure S1). In contrast, C-1A-siRNA was 
undetectable in dorsal hippocampal neurons, located much closer to the infusion site 
(Supplementary Figure S2). Additional experiments using a Cy3-coupled, 
sertraline-conjugated -18-mer oligonucleotide (see Methods) showed that 24h after 
its infusion into the D3V (30µg), the Cy3 labeled oligonucleotide was found in the 
cytoplasm of TPH-positive midbrain serotonin neurons (Supplementary Figure S3).   
Next, we evaluated whether the i.c.v. infusion of C-1A-siRNA could selectively 
silence the 5-HT1AR gene in 5-HT neurons, as observed after local infusion of 
unmodified 1A-siRNA.28 Mice were stereotaxically injected into D3V with: a) vehicle, 
b) unmodified nonsense siRNA (ns-siRNA), c) unmodified 1A-siRNA, d) conjugated 
nonsense siRNA (C-ns-siRNA), or e) C-1A-siRNA (30µg of each siRNA). Histological 
examination at 1-3 days post-administration revealed that 5-HT1AR mRNA and 
binding densities were significantly decreased in the dorsal (40% versus control) and 
median raphe (30%) nuclei of C-1A-siRNA-treated mice (Figure 2a, 2c, 
Supplementary Figure S4).  
A similar decrease was produced by intra-DR infusion of the same unmodified 
1A-siRNA sequences (Supplementary Figure S5). Likewise, local 1A-siRNA and C-
1A-siRNA infusion reduced comparably 5-HT1AR binding density in the DR 
(Supplementary Figure S6), indicating that sertraline conjugation did not alter 1A-
siRNA capacity to knockdown 5-HT1AR.  
In contrast, C-1A-siRNA infusion into D3V did not affect postsynaptic 5-HT1AR 
density in forebrain (Figure 2b, 2d, Supplementary Figure S7a) nor that of other 
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genes expressed by 5-HT neurons (SERT and 5-HT1BR) of the same mice (Figure 
3a-c). Likewise, C-1A-siRNA sequences did not up-regulate inflammatory cytokines 
(TNFα and IFNγ) or apoptotic genes (BAX), while the immunostimulatory activity of 
ß-galactosidase-siRNA sequence (used as positive control) dramatically increased 
TNFα and IFNγ expression (Figure 3d-f), indicating that 5-HT1A-autoreceptor 
silencing was specifically mediated by an RNAi mechanism.  
 
Effects of C-1A-siRNA on serotonergic function 
The physiological consequences of 5-HT1A-autoreceptor silencing were examined 
using the hypothermia response induced by the selective 5-HT1AR agonist, 8-OH-
DPAT, an effect mediated exclusively by presynaptic 5-HT1AR in mice.30 C-1A-
siRNA-treated mice did not show hypothermia, nor did constitutive 5-HT1AR knockout 
mice (1A-KO), while control groups displayed the expected hypothermic response 
(Figure 2e, Supplementary Figure S8a). We next investigated the consequences of 
5-HT1A-autoreceptor knockdown on serotonergic function. Baseline extracellular 5-HT 
concentration in mPFC did not differ among experimental groups (Supplementary 
Table S3). However, 8-OH-DPAT administration (0.5mgkg-1, i.p.) reduced 
extracellular 5-HT concentration in mPFC of vehicle (56% of baseline) and C-ns-
siRNA-treated mice (60%), but not in C-1A-siRNA-treated (88%) and 1A-KO mice 
(99%) (Figure 2f, Supplementary Figure S8b). 
To assess the involvement of SERT as a gate for the accumulation of C-1A-
siRNA in 5-HT neurons, mice were pretreated with sertraline (20 mgkg-1, i.p.; 3h 
before the i.c.v. C-1A-siRNA infusion). These mice displayed the fall in 5-HT release 
and body temperature as did controls, whereas those treated with C-1A-siRNA alone 
did not respond to 8-OH-DPAT in both experimental approaches (Figure 2e-f, 
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Supplementary Figure S8). This indicates that C-1A-siRNA requires functional 
SERT sites to silence 5-HT1A-autoreceptor expression. 
 
C-1A-siRNA evokes antidepressant-like responses  
To explore the behavioral effects of 5-HT1A-autoreceptor knockdown, we examined 
the antidepressant- and anxiety-like responses using the forced swim test (FST), tail 
suspension test (TST), and elevated plus-maze (EPM) paradigm. Mice infused with 
C-1A-siRNA (30µg) into the D3V displayed a marked reduction of immobility time in 
FST compared to controls (Figure 4a). Moreover, C-1A-siRNA-treated mice showed 
a significantly lower immobility than controls in the TST, as did 1A-KO mice (Figure 
4b). A quantitative difference between both groups was noted, likely due to the partial 
knockdown of 5-HT1A-autoreceptors in C-1A-siRNA-treated mice and total absence in 
1A-KO mice. Fluoxetine administration (10mgkg-1, i.p.), used as a positive control, 
also reduced immobility in the FST and TST (Figure 4a-b). In contrast, control and 
C-1A-siRNA-treated mice behaved comparably in the EPM, with equal number of 
entries and time spent in the open arms. 1A-KO mice showed a clear anxiogenic 
profile, as previously described15,31 (Figure 4c). At the neurochemical level, 
fluoxetine (20mgkg-1, i.p.) increased extracellular 5-HT concentration in mPFC 
significantly more in C-1A-siRNA (272% of baseline) and 1A-KO mice (230%) than in 
controls (vehicle: 138%; C-ns-siRNA: 150%), indicating that C-1A-siRNA-induced 
reduction in 5-HT1A-autoreceptors augments SSRI effects (Figure 4d).  
 
Intranasal C-1A-siRNA administration reduces 5-HT1A-autoreceptor expression and 
induces antidepressant effects 
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The above findings support the potential of C-1A-siRNA as a new antidepressant 
strategy, either as monotherapy or in combination with 5-HT-enhancing drugs. 
However, its therapeutic use is limited by the lack of a suitable route to brain. We 
therefore examined the potential of the non-invasive intranasal route, as described 
before.32-34 Intranasal C-1A-siRNA administration (30µg/mouse, as in i.c.v. studies) 
reduced 5-HT1AR mRNA and binding density (27%) in the DR, but not in postsynaptic 
sites in the same mice (Figure 5a-d, Supplementary Figure S7b).  Unlike in 
controls (vehicle and C-ns-siRNA), 8-OH-DPAT administration did not reduce body 
temperature and 5-HT release in mice treated intranasally with C-1A-siRNA (Figure 
5e-f).  
Given the smaller effect size of 30µg intranasal C-1A-siRNA on 5-HT1A-
autoreceptor expression -compared with i.c.v. infusion-, we conducted behavioral 
experiments using 30 and 100µg of intranasal C-1A-siRNA. Both doses significantly 
reduced immobility in the TST, with a greater effect of the 100µg dose (Figure 5g). 
Similarly, intranasal C-1A-siRNA (100µg) evoked a reduction of immobility time in the 
FST which was significantly lower than that seen in controls (Figure 5h). Neither 
dose affected anxiety-like behavior as assessed with EPM test (data not shown). 
 
Discussion 
The present findings show that C-1A-siRNA can be used to efficiently and selectively 
silence 5-HT1A-autoreceptor expression and function in vivo. This represents a new 
therapeutic approach in neuropsychopharmacology, based on the use of RNAi. 
Hence, i.c.v. and intranasal C-1A-siRNA infusion i) reduced 5-HT1A-autoreceptor 
expression, without affecting that of postsynaptic 5-HT1AR, ii) suppressed the 
hypothermia and fall in 5-HT release induced by 8-OH-DPAT; iii) evoked a marked 
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antidepressant-like response in the FST and TST, and iv) augmented the SSRI-
induced elevation of extracellular 5-HT.  
siRNAs are effective, safe and well tolerated in mice and non-human primates. 
While they are used therapeutically in other medical areas, their applicability to brain 
diseases has been hampered by the difficulty to target selected neuronal populations 
and by the lack of adequate delivery methods.27 The present results represent a 
major advance in this field given the selective targeting of 5-HT1AR expressed in 5-
HT neurons after i.c.v. and intranasal administration. Although further investigations 
are required to examine the exact mechanism(s) used by C-1A-siRNA to accumulate 
into 5-HT neurons, available evidence suggests that C-1A-siRNA can be internalized 
via SERT, similarly to SSRI35 to reach the somatodendritic region of serotonergic 
neurons via retrograde axonal transport. This view is supported by i) the selective 
presence of sertraline-conjugated C-1A-siNA and the C-ns-oligonucleotide in 
midbrain serotonergic neuropil and cell bodies, respectively,  ii) its selective action on 
5-HT1A-autoreceptors (far from the infusion site), iii) the lack of effect on hippocampal 
5-HT1AR -much closer to the D3V-, and iv) the prevention of C-1A-siRNA effects by 
prior SERT blockade. The present procedure offers unprecedented efficacy and 
cellular selectivity, compared with previous siRNA conjugation methods used in 
vivo.27,36-38 Hence, the 40% knockdown of 5-HT1A-autoreceptors produced by single-
point administration of 30µg C-1A-siRNA is comparable to previous results using 
prolonged infusion of unmodified siRNA to silence monoamine transporters (400 
µgday-1 for 1-2 weeks; 2.8-5.6mg in total, i.e., 90-180-fold the dose used herein).39,40  
Our results agree with previous observations on the detrimental role of 5-HT1A-
autorerceptors in depression. Human neuroimaging studies have associated high 5-
HT1A-autoreceptor levels with a poor amygdale reactivity.41 Likewise, genetic studies 
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link 5-HT1AR mutations leading to high levels of 5-HT1A-autoreceptors with higher 
incidence of mood disorders and poorer response to antidepressants.7 In rodents, 
disruption of the 5-HT1A-autoreceptor-mediated negative feedback with 5-HT1AR 
antagonists enhances SSRI effects.5,6 Clinically, the non-selective 5-HT1AR 
antagonist pindolol augments and accelerates SSRI effects, likely by a preferential 
interaction with 5-HT1A-autoreceptors.11,12,42 The present data support that C-1A-
siRNA could be used to acutely suppress 5-HT1A-autoreceptor function, without the 
need to wait for antidepressant-induced desensitization, thus optimizing 
antidepressant action.  
Our results also agree with those found recently using conditional knockout 
mice for presynaptic 5-HT1AR.43 Both studies indicate that the selective –yet partial- 
reduction of 5-HT1A-autoreceptor expression with unchanged postsynaptic 5-HT1AR 
expression evokes antidepressant-like behavior and augments SSRI effects. 
Interestingly, the RNAi strategy can be applied in adult mice, without the unwanted 
neurodevelopmental effects associated to 5-HT1AR suppression.44 Although further 
improvements are required, the intranasal route offers a first potential way for C-1A-
siRNA delivery to brain. This route allowed the same effects than the i.c.v. infusion, 
yet with a slightly smaller effect size, likely due to the dilution of C-1A-siRNA during 
brain entry. Once crossed the semi-permeable nasal blood-brain barrier, C-1A-siRNA 
molecules may reach the dense plexus of serotonergic axons in outer layers of the 
olfactory bulb, anatomically connected with olfactory regions.45  
In summary, our results show for the first time the feasibility of using RNAi 
strategies for the treatment of mood disorders. The excellent cellular selectivity and 
efficacy obtained with acute C-1A-siRNA treatment indicate that this may be a new 
approach to treat mood disorders and open the way to develop RNAi-based 
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therapeutic classes to silence genes, or variant alleles refractory to classical 
pharmacological treatments. 
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Figure Legends  
 
Figure 1. (a) Chemical structure of conjugated 5-HT1AR-siRNA (C-1A-siRNA). C-1A-
siRNA construct comprising specific siRNA sequences directed against 5-HT1AR with 
chemical conjugation in each 5’-end strand. The sense strand was aminomodified by 
performing a 5’-C6 amino modification and condensation with a succinimide active 
ester of sertraline (sertraline-NH-CH2C(=O)NH(CH2)5COO-succinimide) making up 
the peptide linker of the conjugate (sertraline-NH-CH2C(=O)NH(CH2)5COO-sense 
strand-3’OH). A phosphoramidite derivative of 1’,2’-dideoxyribose molecule (dSpacer 
CE Phosphoramidite: 5'-O-Dimethoxytrityl-1',2'-Dideoxyribose-3'-[(2-cyanoethyl)-
(N,N-diisopropyl)]phosphoramidite) and two phosphoramidite C18 spacer  arms 
(Spacer Phosphoramidite 18: 18-O-Dimethoxytritylhexaethyleneglycol,1-[(2-
cyanoethyl)-(N,N-diisopropyl)] phosphoramidite) were covalently coupled to the 
complementary antisense strand by phosphodiester linkages.  (b) Selective 
accumulation of C-1A-siRNA in raphe serotonin neurons. Mice received a single 
intracerebroventricular infusion of vehicle or biotin-labeled C-1A-siRNA (30µg) into 
the dorsal third ventricle and were killed 48h post-administration (n=3 mice/group).  
Laser confocal images of TPH-immunoreactive serotonin neurons (blue) showing the 
immune-localized biotin-labeled C-1A-siRNA (red). Right-hand panels are high-
magnification photomicrographs of the frames in the left. Scale bars: white=60μm, 
yellow=25μm.  
 
Figure 2. Selective 5-HT1A-autoreceptor silencing by intracerebroventricular infusion 
of C-1A-siRNA. (a) Representative coronal brain sections showing the C-1A-siRNA-
induced reduction of 5-HT1AR expression in raphe nuclei assessed by in situ 
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hybridization and [3H]-8-OH-DPAT binding. (b) Representative coronal brain sections 
showing [3H]-8-OH-DPAT binding to 5-HT1AR in medial prefrontal cortex (mPFC) and 
hippocampus (HPC). Scale bars: white=2mm, black=500µm. (c) Effect of C-1A-
siRNA (30µg) on 5-HT1AR mRNA and binding in dorsal raphe nucleus (DR) (n=3-5). 
One-way ANOVA revealed a group effect on 5-HT1AR mRNA (F4,15=7.15, P<0.01) 
and 5-HT1AR binding (F4,13=5.04, P<0.05).  *P<0.05, **P<0.01 versus the rest of 
experimental groups. (d) Postsynaptic 5-HT1AR binding in mPFC and HPC was not 
affected by any treatment (n=3-4). (e) The 5-HT1AR agonist, 8-OH-DPAT (1mgkg-1, 
i.p.) reduced body temperature in vehicle and C-ns-siRNA, but not in C-1A-siRNA 
and 1A-KO mice. Pretreatment (3h) with sertraline (20mgkg-1, i.p.) blocked C-1A-
siRNA (30µg) effect on 5-HT1A-autoreceptor silencing (n=5-8). One-way ANOVA, 
F5,31=25.35, P<0.001. (f) 8-OH-DPAT (0.5mgkg-1, i.p.) decreased extracellular 
serotonin in controls, but not in C-1A-siRNA and 1A-KO groups. Pretreatment (3h) 
with sertraline (20mgkg-1, i.p.) prevented the effect of C-1A-siRNA (n=5-8, 
F6,38=15.74, P<0.001). ***P<0.001 versus control groups, ###P<0.001 versus C-1A- 
siRNA. Values are mean ± s.e.m.  
 
Figure 3. (a-c) Unchanged serotonin transporter (SERT) and 5-HT1BR expression 
after 5-HT1A-autoreceptors silencing. Mice received: a) vehicle, b) C-ns-siRNA, or c) 
C-1A-siRNA (30µg) into D3V and were killed 24h after administration (n=5-7). (a) The 
levels of the mRNAs encoding 5-HT1A, SERT and 5-HT1B (serotonin pathway) were 
evaluated in midbrain raphe nuclei by RT-qPCR. One-way ANOVA showed a group 
effect on 5-HT1AR mRNA levels (F2,13=6.06, P<0.05). *P<0.05 versus vehicle and C-
ns-siRNA. (b) Quantitative autoradiography of [3H]-citalopram binding showed no 
differences on SERT density in the different brain areas for each treatment. (c) Bar 
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graph showing no differences in 5-HT1BR density evaluated by [125I]-cyanopindolol 
binding in the different brain areas. mPFC-medial prefrontal cortex; HPC-
hippocampus; DR-dorsal raphe nucleus; GP-globus pallidus; SN-substantia nigra. (d-
f) Unmodified 1A-siRNA and C-1A-siRNA sequences did not induce inflammatory 
and apoptotic responses. (d) Mice received intra-DR: a) vehicle, b) unmodified ns-
siRNA or c) unmodified 1A-siRNA (10µg by 2 consecutive days, 20µg in total) and 
were killed 24h after administration. mRNA levels of TNFα and IFNγ (pro-
inflammatory cytokines) and BAX (apoptosis pathway) were evaluated in midbrain 
raphe nuclei by RT-qPCR (n=4-6). (e) Immunostimulatory β-Gal-siRNA was used as 
a positive control. Mice received intra-DR: a) vehicle, or b) β-Gal-siRNA (10µg by 2 
consecutive days, 20µg in total) and were killed 24h after administration. TNFα and 
IFNγ mRNA levels were significantly up-regulated in midbrain after β-Gal-siRNA 
infusion (n=3-6, Student's t-test, ***P<0.001).  (f) Bar graphs showing no differences 
in TNFα, IFNγ and BAX mRNA levels of mice infused with: a) vehicle, b) C-ns-siRNA 
or c) C-1A-siRNA (30µg) into D3V and killed 24h after administration (n=5-7).  Values 
are mean ± s.e.m.   
 
Figure 4. C-1A-siRNA evokes antidepressant-like responses and potentiates the 
neurochemical effect of fluoxetine. (a) Mice infused with 30µg C-1A-siRNA in the 
dorsal third ventricle (D3V) displayed a decreased immobility in the forced swim test 
(FST) (n=14-15). Two-way ANOVA showed a significant effect of group (F1,27=12.98, 
P<0.001), time (F2,54=150.05, P<0.0001) and interaction (F2,54=3.18, P<0.05). A 
significantly greater reduction of the immobility in C-1A-siRNA-treated mice vs. 
controls was observed for the total period (0-6min) (P<0.01; Student’s t-test). A 
comparable antidepressant response was observed after acute SSRI fluoxetine 
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administration to control C57BL/6J mice (10mgkg-1, i.p. 30min before FST) (n=12-
13). Effect of group (F1,23=5.18, P<0.05) and time (F2,46=66.94, P<0.0001). Student's 
t-test was used to assess the action of fluoxetine for the total observation period (0-
6min). *P<0.05, **P<0.01, ***P<0.001 versus respective controls. (b) C-1A-siRNA-
treated mice also showed a reduced immobility in the tail suspension test (TST), as 
did constitutive 1A-KO mice (n=12-18). One-way ANOVA showed a significant effect 
of group (F2,47=18.64, P<0.001). Acute fluoxetine administration (10mgkg-1, i.p. 1h 
before TST) produced a similar antidepressant response (n=7). **P<0.01, ***P<0.001 
versus vehicle mice, ##P<0.01 versus C-1A-siRNA mice. (c) Unlike 1A-KO mice, 
vehicle and C-1A-siRNA mice behaved similarly in the elevated plus-maze (n=12-18). 
One-way ANOVA indicated a group effect on entries (F2,43=24.18, P<0.001) and time 
in open arms (F2,42=4.56, P<0.05). *P<0.05, **P<0.01, ***P<0.001 versus vehicle and 
C-1A-siRNA groups. (d) Acute fluoxetine (20 mgkg-1, i.p.) increased extracellular 
serotonin in mPFC of C-1A-siRNA and 1A-KO mice significantly more than in vehicle 
and C-ns-siRNA groups (n=4-6). Effect of group (F3,17=4.78, P<0.05), time 
(F14,238=19.40, P<0.001) and interaction (F42,238=2.57, P<0.001). *P<0.05 versus 
control groups. Values are mean ± s.e.m.  
 
Figure 5. Intranasal C-1A-siRNA silences 5-HT1A-autoreceptors and evokes 
antidepressant-like responses.  (a) Representative coronal brain sections showing 
the C-1A-siRNA-induced reduction of 5-HT1AR expression in raphe nuclei by in situ 
hybridization and [3H]-8-OH-DPAT binding. (b) Representative coronal brain sections 
showing [3H]-8-OH-DPAT binding to 5-HT1AR in medial prefrontal cortex (mPFC) and 
hippocampus (HPC). Scale bars: white=2mm, black=500µm. (c) Bar graphs showing 
the effects of intranasal C-1A-siRNA (30µg) administration on 5-HT1AR mRNA and 
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binding in dorsal raphe nucleus (DR) (n=3-6). One-way ANOVA showed a significant 
effect of group on 5-HT1AR mRNA (F2,9=12.41, P<0.01) and 5-HT1AR binding 
(F2,8=37.98, P<0.001). *P<0.05, **P<0.01 versus control groups. (d) Unchanged 
densities of postsynaptic 5-HT1AR binding in all experimental groups (n=3-6). (e) 
Systemic 8-OH-DPAT administration (1 mgkg-1, i.p.) did not evoke hypothermia in C-
1A-siRNA-treated (30μg) mice (n=5-7). Two-way ANOVA showed a significant effect 
of group (F2,13=34.21, P<0.001), time (F4,52=59.30, P<0.001) and interaction 
(F8,52=10.89, P<0.001). ***P<0.001 versus control groups. (f) Reduced extracellular 
serotonin in mPFC of controls, but not in C-1A-siRNA mice after 8-OH-DPAT 
administration (0.5mgkg-1, i.p.) (n=4-6). Significant effect of group (F2,12=8.22, 
P<0.01), time (F14,168=7.56, P<0.001) and interaction (F28,168=2.28, P<0.001). 
**P<0.01 versus controls. (g) Single intranasal C-1A-siRNA administration (30 or 
100μg) evoked a dose-dependent decreased immobility in the tail suspension test 
(n=10-15). One-way ANOVA showed a significant effect of group (F2,34=8.70, 
P<0.001). *P<0.05, ***P<0.001 versus vehicle. (h) Mice treated intranasally with C-
1A-siRNA (100μg) displayed a reduced immobility time in the forced swim test 
compared with vehicle-treated controls (n=13-16). Two-way ANOVA showed a 
significant effect of group (F1,27=9.27, P<0.01) and time (F2,54=102.95, P<0.0001). 
Student's t-test was used to assess the action of C-1A-siRNA for the total 
observation period (0-6min). **P<0.01 versus vehicle.  Values are mean ± s.e.m.  
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